Huntington's disease progression. PET and clinical observations

Brain

Volumn 122, Issue 12, 1999, Pages 2353-2363

  Andrews, Thomasin C ^a   Weeks, Robert A ^a   Turjanski, Nora ^a   Gunn, Roger N ^a   Watkins, Laura H A ^c   Sahakian, Barbara ^c   Hodges, John R ^d   Rosser, Anne E ^c   Wood, Nicholas W ^b   Brooks, David J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

Author keywords

Disease progression; Dopamine receptors; Huntington's disease; PET; UHDRS

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; RACLOPRIDE; TETRABENAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BINDING;

EID: 0032747164     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.12.2353     Document Type: Article

References (47)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75.
2. 11C]-raclopride. Ann N Y Acad Sci 1993; 695: 81-5.
3. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996; 119: 2085-95.
4. 11C]Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998; 43: 253-5.
5. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997; 42: 215-21.
6. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994; 44: 823-8.
7. Brandt J, Folstein SE, Wong DF, Links J, Dannals RF, McDonnell-Sill A, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 1990; 2: 20-7.
8. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update [see comments]. [Review]. Trends Neurosci 1996; 19: 417-22. Comment in: Trends Neurosci 1997; 20: 152-3.
9. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update [see comments]. [Review]. Trends Neurosci 1996; 19: 417-22. Comment in: Trends Neurosci 1997; 20: 152-3.
10. Davis MB, Bateman D, Quinn NP, Marsden CD, Harding AE. Mutation analysis in patients with possible but apparently sporadic Huntington's disease. Lancet 1994; 344: 714-7.
11. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease [see comments]. Nat Genet 1993; 4: 387-92. Comment in: Nat Genet 1993; 4: 329-30.
12. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease [see comments]. Nat Genet 1993; 4: 387-92. Comment in: Nat Genet 1993; 4: 329-30.
13. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr, Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987; 411: 162-6.
14. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. [Review]. Trends Neurosci 1997; 20: 482-7.
15. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996; 39: 132-6.
16. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997; 120: 503-14.
17. Grafton ST, Mazziotta JC, Pahl JJ, St. George-Hyslop P, Haines JL, Gusella J, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992; 49: 1161-7.
18. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985; 227: 770-3.
19. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-87.
20. Hagglund J, Aquilonius SM, Eckernas SA, Hartvig P, Lundquist H, Gullberg P, et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol Scand 1987; 75: 87-94.
21. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
22. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-42.
23. Hussey D, Stewart D, Houle S, Guttman M. [c-11] raclopride striatal binding potential as a measure of Huntington's disease progression: implications for prospective neuroprotective studies [abstract]. J Nucl Med 1998; 39 Suppl: 209P.
24. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988; 2: 546-57.
25. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-8.
26. 11C]raclopride studies. J Cereb Blood Flow Metab 1996; 16: 42-52.
27. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord 1986; 1: 69-77.
28. Marshall FJ, Shoulson I. Clinical features and treatment of Huntington's disease. In: Watts RL and Koller WC. editors. Movement disorders: neurological principles and practice. New York: McGraw Hill; 1997. p. 491-502.
29. Mintun MA, Raichle ME, Kilbourn MR, Woolen GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-27.
30. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-9.
31. Penney JB Jr, Young AB. Striatal inhomogeneities and basal ganglia function. [Review]. Mov Disord 1986; 1: 3-15.
32. Rappaport MS, Sealfon SC, Prikhozhan A, Huntley GW, Morrison JH. Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum. Brain Res 1993; 616: 242-50.
33. Richfield EK, O'Brien CF, Eskin T, Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett 1991; 132: 121-6.
34. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med 1991; 14: 9-30.
35. Rubinsztein DC, Leggo J, Chiano M, Dodge A, Norbury G, Rosser E, et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997; 94: 3872-6.
36. Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, et al. Dopamine D1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994; 243: 249-55.
37. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's Disease Rating Scale: a follow up. Move Disord 1998; 13: 915-9.
38. Simpson SA, Harding AE. Predictive testing for Huntington's disease: after the gene. The United Kingdom Huntington's Disease Prediction Consortium. J Med Genet 1993; 30: 1036-8.
39. Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci 1988; 35: 721-5.
40. Spinks TJ, Jones T, Bailey DL, Townsend DW, Grootoonk S. Bloomfield PM, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992; 37: 1637-55.
41. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24: 25-35.
42. Surmeier DJ, Reiner A, Levine MS, Ariano MA. Are neostriatal dopamine receptors co-localized? [see comments]. [Review]. Trends Neurosci 1993; 16: 299-305. Comment in: Trends Neurosci 1994; 17: 2-5.
43. Surmeier DJ, Reiner A, Levine MS, Ariano MA. Are neostriatal dopamine receptors co-localized? [see comments]. [Review]. Trends Neurosci 1993; 16: 299-305. Comment in: Trends Neurosci 1994; 17: 2-5.
44. Torres EM, Fricker RA, Hume SP, Myers R, Opacka-Juffry J, Ashworth S, et al. Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. Neuroreport 1995; 6: 2017-21.
45. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995; 118: 689-96.
46. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain [published erratum appears in J Nucl Med 1993; 34: 838]. J Nucl Med 1993; 34: 609-13.
47. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996; 40: 49-54.